These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34776840)

  • 1. Role of Multifocal Visually Evoked Potential as a Biomarker of Demyelination, Spontaneous Remyelination, and Myelin Repair in Multiple Sclerosis.
    Klistorner A; Graham SL
    Front Neurosci; 2021; 15():725187. PubMed ID: 34776840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
    Lazzarotto A; Hamzaoui M; Tonietto M; Dubessy AL; Khalil M; Pirpamer L; Ropele S; Enzinger C; Battaglini M; Stromillo ML; De Stefano N; Filippi M; Rocca MA; Gallo P; Gasperini C; Stankoff B; Bodini B;
    Brain; 2024 Apr; 147(4):1331-1343. PubMed ID: 38267729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy.
    Cordano C; Sin JH; Timmons G; Yiu HH; Stebbins K; Guglielmetti C; Cruz-Herranz A; Xin W; Lorrain D; Chan JR; Green AJ
    Brain; 2022 Nov; 145(11):3943-3952. PubMed ID: 35678509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis.
    Sekyi MT; Lauderdale K; Atkinson KC; Golestany B; Karim H; Feri M; Soto JS; Diaz C; Kim SH; Cilluffo M; Nusinowitz S; Katzenellenbogen JA; Tiwari-Woodruff SK
    Brain Pathol; 2021 Mar; 31(2):312-332. PubMed ID: 33368801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evoked potentials as a biomarker of remyelination.
    Heidari M; Radcliff AB; McLellan GJ; Ver Hoeve JN; Chan K; Kiland JA; Keuler NS; August BK; Sebo D; Field AS; Duncan ID
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):27074-27083. PubMed ID: 31843913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
    Keirstead HS; Blakemore WF
    Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryogel scaffolds for regionally constrained delivery of lysophosphatidylcholine to central nervous system slice cultures: A model of focal demyelination for multiple sclerosis research.
    Eigel D; Zoupi L; Sekizar S; Welzel PB; Werner C; Williams A; Newland B
    Acta Biomater; 2019 Oct; 97():216-229. PubMed ID: 31425890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain region dependent molecular signatures and myelin repair following chronic demyelination.
    Samtani G; Kim S; Michaud D; Hillhouse AE; Szule JA; Konganti K; Li J
    Front Cell Neurosci; 2023; 17():1169786. PubMed ID: 37180951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-WRAP (Remyelination for women at risk of axonal loss and progression): A phase II randomized placebo-controlled delayed-start trial of bazedoxifene for myelin repair in multiple sclerosis.
    Nylander A; Anderson A; Rowles W; Hsu S; Lazar AA; Mayoral SR; Pease-Raissi SE; Green A; Bove R
    Contemp Clin Trials; 2023 Nov; 134():107333. PubMed ID: 37739167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency of Multifocal Visual Evoked Potential in Multiple Sclerosis: A Visual Pathway Biomarker for Clinical Trials of Remyelinating Therapies.
    Klistorner A; Triplett JD; Barnett MH; Yiannikas C; Barton J; Parratt J; You Y; Graham SL
    J Clin Neurophysiol; 2021 May; 38(3):186-191. PubMed ID: 33235179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination.
    Miller DJ; Rodriguez M
    Microsc Res Tech; 1995 Oct; 32(3):230-45. PubMed ID: 8527857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portable Multi-focal Visual Evoked Potential Diagnostics for Multiple Sclerosis/Optic Neuritis patients.
    Banijamali SMA; Versek C; Babinski K; Kamarthi S; Green-LaRoche D; Sridhar S
    medRxiv; 2023 Dec; ():. PubMed ID: 38234795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion kurtosis imaging probes cortical alterations and white matter pathology following cuprizone induced demyelination and spontaneous remyelination.
    Guglielmetti C; Veraart J; Roelant E; Mai Z; Daans J; Van Audekerke J; Naeyaert M; Vanhoutte G; Delgado Y Palacios R; Praet J; Fieremans E; Ponsaerts P; Sijbers J; Van der Linden A; Verhoye M
    Neuroimage; 2016 Jan; 125():363-377. PubMed ID: 26525654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of multifocal visual evoked potentials in patients with optic neuritis and multiple sclerosis: a review.
    Zafeiropoulos P; Katsanos A; Kitsos G; Stefaniotou M; Asproudis I
    Doc Ophthalmol; 2021 Jun; 142(3):283-292. PubMed ID: 33381858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes.
    Wooliscroft L; Altowaijri G; Hildebrand A; Samuels M; Oken B; Bourdette D; Cameron M
    Mult Scler Relat Disord; 2020 Jun; 41():102015. PubMed ID: 32120028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination.
    Silvestroff L; Bartucci S; Pasquini J; Franco P
    Exp Neurol; 2012 May; 235(1):357-67. PubMed ID: 22421533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis.
    Gharagozloo M; Mace JW; Calabresi PA
    Front Mol Neurosci; 2022; 15():995477. PubMed ID: 36407761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin recovery in multiple sclerosis: the challenge of remyelination.
    Podbielska M; Banik NL; Kurowska E; Hogan EL
    Brain Sci; 2013 Aug; 3(3):1282-324. PubMed ID: 24961530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test.
    Saridas F; Hojjati F; Alizada S; Lazrak S; Koc ER; Turan OF
    Mult Scler Relat Disord; 2024 Nov; 91():105850. PubMed ID: 39232395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis.
    Cadenas-Fernández J; Ahumada-Pascual P; Andreu LS; Velasco A
    Curr Pharm Des; 2021 Oct; 27(30):3273-3280. PubMed ID: 33504299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.